There is no known contraindication to using tirzepatide and sermorelin together, but no controlled clinical trials have evaluated this combination's safety or efficacy
Weight-loss benefits should also be judged alongside nutrition, strength, sleep, mental health, and chronic disease care
Safety concerns, patent and affordability issues collide The FDA has warned about potentially substandard quality, unlabeled salt forms, and dosing errors in compounded versions
Front Endocrinol (Lausanne) (2021) 12:620566
India First generics of semaglutide will launch in early 2026 after Novo Nordisks patent expires in January 2026
The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects